News | January 09, 2012

SCAAR Registry: Newer Drug-Eluting Stents Have Lower Mortality, Restenosis Than Bare Metal Stents

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower rates of restenosis, stent thrombosis and mortality than older DES and bare-metal stents.

The findings, from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and reported in the European Heart Journal, represent the outcome of treatment in a large "real-world population," and were derived from an analysis of 94,384 consecutive stent implantations performed in Sweden between November 2006 and October 2010.

An earlier study from the SCAAR registry evaluating stent implantations between 2003 and 2004 had shown that those treated with DES had a higher rate of later mortality than those receiving bare-metal stents (BMS). The results caused uproar, and prompted an immediate decline in the use of DES and an urgent review of their safety. However, follow-up of the same patient cohort two years later (with data extended to 2006) found no increased risk of death between the two groups. The difference in outcome was largely explained by improvements in cardiology practice (including the application of dual-antiplatelet therapy after PCI) and the introduction of improved devices.

Conclusions in this latest report, from what is the world's largest PCI registry with the longest follow-up of data, now confirm that mortality rates associated with both the new and old generations of DES were significantly lower than found with BMS. The risk of death was 28 percent lower with the old generation DES and 45 percent lower with the new generation; moreover, the new generation DES were associated with a 23 percent lower mortality rate at two years than the old generation DES.

The authors note that this is the first time any mortality reduction has been shown between DES and BMS, either in randomized trials or in reports from the SCAAR registry itself.

The study also found that the new generation of DES was associated with a 38 percent lower risk of restenosis and a 43 percent lower risk of stent thrombosis within two years of implantation than BMS. Late stent thrombosis has been a recurring safety concern with the original DES; the authors suggest that the new generation DES, with "thin, more biocompatible polymers" and greater flexibility, may have contributed to lowering this thrombotic risk.

Speaking on behalf of the SCAAR investigators, cardiologist Dr. Stefan James from Uppsala University Hospital in Sweden described the latest findings as "intriguing" - not just because of the lower rates of restenosis with the latest generation of DES, which were expected, but also of stent thrombosis and mortality. "The low rates of restenosis and stent thrombosis correspond with the results of several recent randomized trials," said James, "and this may well translate into mortality reduction in a sufficiently large study population."

However, he warned that all observational data should be interpreted with caution. "Despite the use of appropriate statistical methods," he said, "there may be residual confounding because of differences in concealed baseline variables." Nevertheless, this SCAAR analysis included only patients who were treated after 2006, to ensure that both the older and newer generation DES were used. "Since 2006 no major changes in recommendations for antithrombotic strategies or duration of dual antiplatelet therapy have occurred in Sweden," said Dr James, "so it seems likely that our more favorable outcomes are true findings."

The investigators say their results now add further weight to the strong recommendation for the use of DES as a default strategy in patients expected to tolerate extended dual antiplatelet therapy in the treatment of coronary artery disease. "But our results also reinforce the need for randomized trials to evaluate the optimal strategy and duration of antithrombotic therapy following PCI in various indications," said James.

For more information: eurheartj.oxfordjournals.org

 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init